Vistagen Therapeutics, Inc. quarterly report, Q3 FY2023

Vistagen Therapeutics, Inc. — Form 10-Q Summary

Reporting period: Fiscal third quarter and nine months ended December 31, 2022. The quarter was reported on February 7, 2023. Vistagen is a clinical-stage biopharmaceutical company developing CNS therapies; it had no approved products or recurring product-sale revenue.

Financial performance and liquidity

Metric	Three months ended Dec. 31, 2022	Nine months ended Dec. 31, 2022	Comparable 2021 period
Revenue	$179,600	$(402,900)	$357,900; $1.07 million
Research and development	$6.85 million	$35.04 million	$7.78 million; $23.17 million
General and administrative	$3.09 million	$11.59 million	$3.12 million; $8.98 million
Net loss	$9.76 million	$47.02 million	$10.54 million; $31.07 million
Net loss per share	$0.05	$0.23	$0.05; $0.16
Operating cash used	Not presented by quarter	$42.24 million	$29.67 million

• The negative nine-month revenue reflects a $1.475 million cumulative catch-up reduction in previously recognized AffaMed sublicense revenue after Vistagen extended its estimated performance period. The company recognized $179,600 in the December quarter; $3.205 million remained deferred at period end.
• Cash and cash equivalents were $25.04 million at December 31, down from $68.14 million at March 31, 2022. Total assets were $29.71 million and stockholders’ equity was $20.67 million.
• Current assets were $26.06 million and current liabilities $4.29 million. Liabilities included a $419,100 insurance-premium financing note, operating-lease obligations of $2.72 million, and deferred revenue. The filing does not report conventional funded long-term borrowings.
• Net cash used in investing activities was $212,000; financing activities used $644,000. Cash declined by $43.10 million during the nine months. The company stated its cash was not sufficient for planned operations for the 12 months after issuance of the financial statements, raising substantial doubt about its ability to continue as a going concern.
• No meaningful product gross margin was reported. Operating expenses substantially exceeded revenue.

Material changes and operating developments

• For the nine-month period, R&D expense rose $11.87 million year over year, primarily reflecting PH94B and PH10 trials, manufacturing, and regulatory work. G&A expense increased $2.60 million, including professional fees, insurance, stock compensation, investor-relations activity, and pre-commercialization spending.
• PALISADE-1, a Phase 3 PH94B study for social anxiety disorder, failed to meet its primary efficacy endpoint in July 2022; reported safety and tolerability were favorable. Vistagen paused enrollment in PALISADE-2 and ended enrollment in the open-label study. It was consulting the FDA on a broader Phase 3 plan, potentially using repeated as-needed dosing and the LSAS measure; no final plan was disclosed.
• Vistagen completed an exploratory Phase 2A PH94B study in adjustment disorder with anxiety in January 2023 and expected top-line results by the end of the first calendar quarter of 2023.
• The FDA granted Fast Track designation to PH10 for major depressive disorder in December 2022 and allowed a U.S. Phase 1 study to proceed. The study began dosing in January 2023; the company anticipated completion by the end of the first calendar quarter of 2023.
• AV-101 was being studied with probenecid in an exploratory Phase 1B interaction study, with final-cohort dosing expected in the first half of 2023. Vistagen also reported Fast Track designations for AV-101 in adjunctive MDD and neuropathic pain.
• After quarter-end, on February 2, 2023, Vistagen completed its acquisition of Pherin Pharmaceuticals. It issued 12.41 million shares and paid approximately $125,800 in cash consideration, obtaining full ownership of PH94B and PH10 intellectual property and three early-stage candidates: PH15, PH80, and PH284. This subsequent event was not reflected in December 31 balances.

Outlook, risks, and unusual items

• Management expected continued losses and negative operating cash flows and planned to seek additional financing through equity or debt, grants, and partnerships. No quantified financial guidance was provided. The company cautioned that funding might not be available on acceptable terms or in time.
• Vistagen received a Nasdaq notice in September 2022 for failure to meet the $1.00 minimum bid-price requirement, with an initial compliance deadline of March 6, 2023. A reverse stock split was an available potential remedy; delisting could impair share liquidity and access to capital.
• The PALISADE-1 outcome delayed PH94B development and led to revised timing estimates under the AffaMed agreement and a revenue catch-up adjustment. Two peer companies also reported unsuccessful SAD studies using a similar public-speaking challenge design, adding uncertainty around that methodology.
• The company cited clinical-trial failure or delay, regulatory approval, reliance on CROs and manufacturers, COVID-19-related disruptions, competition, intellectual-property protection, dilution, and financing availability as material risks.
• Unusual reported items included the revenue catch-up adjustment, $77,400 expense from extending the term of warrants, and a $300,000 accrued estimated liability related to a former employee. The company reported no legal proceedings and no off-balance-sheet arrangements.

Key facts for investors to verify

• Current cash runway, expected burn rate, and timing, amount, and terms of any financing or strategic partnership.
• FDA feedback and the finalized PH94B Phase 3 design, including the decision on PALISADE-2 and the primary endpoint.
• Top-line results from the PH94B adjustment-disorder study and results and next steps for the PH10 Phase 1 study.
• Development plans and expected costs for AV-101 and the three Pherin-acquired candidates; confirm post-acquisition share count and accounting treatment.
• Nasdaq listing compliance status and any reverse-split action, as well as potential dilution from equity issuance and outstanding options and warrants.
• Progress in resolving the going-concern uncertainty and whether deferred AffaMed revenue estimates change again.